dexamethasone + venetoclax + azacitidine

Dexamethasone + venetoclax + azacitidine is an investigational combination regimen being evaluated by the University of Vermont for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients who are ineligible for intensive chemotherapy. This regimen adds dexamethasone, a synthetic glucocorticoid and anti-inflammatory agent, to the standard-of-care backbone of venetoclax (a BCL-2 inhibitor) and a low-intensity therapy (LIT), most commonly the hypomethylating agent azacitidine. The addition of dexamethasone is hypothesized to improve the safety, tolerability, and potentially the clinical efficacy of the venetoclax-based LIT. The Phase 1b DLIT-AML trial (NCT05542407) is specifically designed to assess the safety and tolerability of this combination in treatment-naïve AML patients.

Other names

Dexamethasone plus Venetoclax-based Low-Intensity TherapyD-V-LITdexamethasone + venetoclax + decitabinedexamethasone + venetoclax + cytarabine